Coya Therapeutics, a clinical-stage biotechnology firm specializing in biologics to enhance regulatory T cell (Treg) function, will present data from its phase 2, double-blind, placebo-controlled study of interleukin-2 (IL-2) for mild to moderate Alzheimer’s Disease at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD24). The study, conducted at the Houston Methodist Research Institute and supported by the Gates Foundation and Alzheimer’s Association, will be showcased in Madrid, Spain, from October 29 to November 1, 2024. Dr. Alireza Faridar, Principal Investigator, expressed his anticipation for presenting the dataset and extended his gratitude to the patients, families, and supporting organizations.
Alzheimer’s disease is the leading cause of dementia, affecting up to 80% of dementia cases, with an estimated 5.7 million Americans impacted. Symptoms typically emerge after age 60, with the incidence doubling every 5 years past age 65. It is a progressive condition that worsens over time, starting with mild memory loss and advancing to severe cognitive decline. Alzheimer’s is the sixth leading cause of death overall and the fifth for those aged 65 or older. Patients generally live 4 to 8 years post-diagnosis, though some may live up to 20 years.
About COYA 301 and COYA 302
- COYA 301: A proprietary investigational low-dose IL-2 aimed at enhancing the anti-inflammatory function of Tregs, designed for subcutaneous administration. It is not yet FDA-approved.
- COYA 302: An investigational biologic combination therapy with dual mechanisms—low-dose IL-2 and CTLA4-Ig—targeting Tregs and modulating inflammation. Developed for ALS, FTD, and PD, COYA 302 is in clinical trials and is not FDA-approved.
In February 2023, Coya reported positive results from a proof-of-concept study of LD IL-2 and CTLA4-Ig in ALS patients. The therapy was well tolerated, with no serious adverse events, and demonstrated significant improvements in disease progression and Treg function over 48 weeks.
About Coya Therapeutics, Inc.
Based in Houston, TX, Coya Therapeutics (Nasdaq: COYA) is focused on developing treatments to restore Treg function and address systemic inflammation and neuroinflammation. The company’s pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapies. COYA 302, a key investigational product, combines COYA 301 with CTLA4-Ig to treat neurodegenerative diseases, aiming to balance immune responses and reduce inflammation sustainably.
